By Shaker A. Mousa
1This number of overview articles highlights the newest improvement of antithrombotics and offers confirmed experimental equipment for the extra improvement of recent and better anticoagulants. one of the state-of-the-art advancements reviewed are the radical utilization of low molecular weight heparins, such antithrombin brokers because the hirudin, and such antiplatelet medicinal drugs because the GPIIb/IIIa inhibitors and ADP receptor antagonists. extra techniques mentioned contain aspirin and clopidogrel, the improved use of polytherapeutic techniques, antiproteases (factors IIa, Xa, and VIIa), tissue issue concentrating on, platelet receptor focusing on, and antithrombin III modulation.
Read Online or Download Anticoagulants, Antiplatelets, and Thrombolytics (Methods in Molecular Medicine) PDF
Similar hematology books
This new instruction manual in transfusion medication and hemostasis goals to mix medical and laboratory details from fields that have excessive levels of overlap into one concise, easy-to-use notebook. This complete reference advisor could have the intensity of knowledge to be priceless to all physicians who order and administer blood parts and really good elements for hemostatic abnormalities, in addition to those that seek advice and deal with those usually very in poor health sufferers.
“I simply comprehensive interpreting your bankruptcy concerning the normocytic anemias attributable to hemoglobinopathies, and it used to be so interesting that I forgot that i used to be really learning! you've gotten a true knack for offering details. ”—Joan BleegStudent, college of North Dakota overview of the first EditionBuild a superior realizing of hematology within the context of functional laboratory perform and ideas.
Beverly Teicher and a panel of special investigators survey the cutting-edge of antiangiogenesis learn from the lab bench to scientific trials. well timed and authoritative, the members summarize our present knowing of tumor progress and its dependence on vascular improvement, in addition to the current prestige of antiangiogenic brokers in preclinical and medical improvement.
This sensible new source is helping readers deal with the complete diversity of clotting and bleeding problems quick and successfully. Written by way of a crew of revered clinicians, it examines signs, laboratory findings, analysis, differential analysis, and therapy. A reader-friendly layout and hundreds of thousands of illustrations make it an important instrument for busy physicians.
- Pediatric Cancer in Africa: A Case-Based Guide to Diagnosis and Management
- Head and neck cancer: emerging perspectives
- Molecular and Cellular Aspects of the Serpinopathies and Disorders in Serpin Activity
- Nonmalignant Hematology: Expert Clinical Review: Questions and Answers
- Alternative Toxicological Methods
Extra info for Anticoagulants, Antiplatelets, and Thrombolytics (Methods in Molecular Medicine)
2001) Comparative antiplatelet efficacy of a novel, nonpep- CH03,21-34,14pgs 34 20. 21. 22. 23. 24. 9/5/03 11:01 AM Page 34 McCarty et al. tide GPIIb/IIIa antagonist (XV454) and Abciximab (c7E3) in Flow Models of Thrombosis. Arterioscler. Thromb. Vasc. Biol. 21, 149–156. Turner, N. , Moake, J. , Kamat, S. , Schafer, A. , Kleiman, N. , and McIntire, L. V. (1995) Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
21. Stoen, G. , Grines, C. , Cox, D. , et al. (2002) Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N. Engl. J. Med. 346, 957–966. 22. The SPEED Group (Strategies for the Patency Enhancement in the Emergency Department) (2001) Randomized trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation 101, 2788–2794. 23. Antman, E. , Gibson, C. , de Lemos, J. , et al. (2000) Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14.
The convenient once- or twice daily sc dosing regimen without the need for monitoring has encouraged the wide use of LMWHs. It is well-established that different LMWHs vary in their physical and chemical properties because of the differences in their methods of manufacturing. These differences translate into differences in their pharmacodynamic and pharmacokinetic characteristics (16). The World Health Organization (WHO) and United States Food and Drug Administration (FDA) regard LMWHs as individual drugs that cannot be used interchangeably (16,33).
Anticoagulants, Antiplatelets, and Thrombolytics (Methods in Molecular Medicine) by Shaker A. Mousa